{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T14:41:23Z","timestamp":1776696083295,"version":"3.51.2"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2005,8,18]],"date-time":"2005-08-18T00:00:00Z","timestamp":1124323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2005,8,18]],"date-time":"2005-08-18T00:00:00Z","timestamp":1124323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.1038\/sj.leu.2403873","type":"journal-article","created":{"date-parts":[[2005,8,18]],"date-time":"2005-08-18T13:10:51Z","timestamp":1124370651000},"page":"2063-2071","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Treatment strategy and results in children treated on three Dutch Childhood Oncology Group acute myeloid leukemia trials"],"prefix":"10.1038","volume":"19","author":[{"given":"G","family":"Kardos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C M","family":"Zwaan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G J L","family":"Kaspers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S S N","family":"de-Graaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E S J M","family":"de Bont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Postma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J P M","family":"B\u00f6kkerink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R S","family":"Weening","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"van der Does-van den Berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E R","family":"van Wering","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Korbijn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"H\u00e4hlen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,8,18]]},"reference":[{"key":"BF2403873_CR1","first-page":"146","volume":"46","author":"A Van Der Does-Van Den Berg","year":"1978","unstructured":"Van Der Does-Van Den Berg A, Van Wering ER, Van Zanen GE . Acute niet-lymfatische leukemie\u00ebn bij kinderen in Nederland (1972\u20131977). Tijdschr Kindergeneeskd 1978; 46: 146\u2013153.","journal-title":"Tijdschr Kindergeneeskd"},{"key":"BF2403873_CR2","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1038\/sj.leu.2401964","volume":"14","author":"WA Kamps","year":"2000","unstructured":"Kamps WA, Veerman AJ, Van Wering ER, Van Weerden JF, Slater R, Does-van den Berg A . Long-term follow-up of Dutch Childhood Leukemia Study Group (DCLSG) protocols for children with acute lymphoblastic leukemia, 1984\u20131991. Leukemia 2000; 14: 2240\u20132246.","journal-title":"Leukemia"},{"key":"BF2403873_CR3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3109\/08880018809031259","volume":"5","author":"A Van Der Does-Van Den Berg","year":"1988","unstructured":"Van Der Does-Van Den Berg A, H\u00e4hlen K, Colly LP, Vossen JM . Treatment of childhood acute nonlymphocytic leukemia with high-dose cytosine-arabinoside, 6-thioguanine and doxorubicin without maintenance therapy: pilot study ANLL-80 of the Dutch Childhood Leukemia Study Group. Pediatr Hematol Oncol 1988; 5: 93\u2013102.","journal-title":"Pediatr Hematol Oncol"},{"key":"BF2403873_CR4","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/sj.leu.2403665","volume":"19","author":"AM Slats","year":"2005","unstructured":"Slats AM, Egeler RM, Van Der Does-Van Den Berg A, Korbijn C, H\u00e4hlen K, Kamps WA et al. Causes of death \u2013 other than progressive leukemia \u2013 in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood Oncology Group experience. Leukemia 2005; 19: 537\u2013544.","journal-title":"Leukemia"},{"key":"BF2403873_CR5","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1056\/NEJM198008283030901","volume":"303","author":"HJ Weinstein","year":"1980","unstructured":"Weinstein HJ, Mayer RJ, Rosenthal DS, Camitta BM, Coral FS, Nathan DG et al. Treatment of acute myelogenous leukemia in children and adults. N Engl J Med 1980; 303: 473\u2013478.","journal-title":"N Engl J Med"},{"key":"BF2403873_CR6","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1182\/blood.V75.10.1932.1932","volume":"75","author":"U Creutzig","year":"1990","unstructured":"Creutzig U, Ritter J, Schellong G, for the AML-BFM Study Group. Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. Blood 1990; 75: 1932\u20131940.","journal-title":"Blood"},{"key":"BF2403873_CR7","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1200\/JCO.1993.11.2.279","volume":"11","author":"U Creutzig","year":"1993","unstructured":"Creutzig U, Ritter J, Zimmermann M, Schellong G . Does cranial irradiation reduce the risk for bone marrow relapse in acute myelogenous leukemia? Unexpected results of the Childhood Acute Myelogenous Leukemia Study BFM-87. J Clin Oncol 1993; 11: 279\u2013286.","journal-title":"J Clin Oncol"},{"key":"BF2403873_CR8","first-page":"389","volume":"30","author":"K H\u00e4hlen","year":"1987","unstructured":"H\u00e4hlen K, Van Der Does-Van Den Berg A, Colly LP, Smets LA, Taminiau JA, Vossen JM . Treatment of childhood acute nonlymphocytic leukemia with individually scheduled high doses of cytarabine: preliminary results of study ANLL-82 of the Dutch Childhood Leukemia Study Group (DCLSG). Haematol Blood Transfus 1987; 30: 389\u2013392.","journal-title":"Haematol Blood Transfus"},{"key":"BF2403873_CR9","doi-asserted-by":"publisher","first-page":"620","DOI":"10.7326\/0003-4819-103-4-620","volume":"103","author":"JM Bennett","year":"1985","unstructured":"Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French\u2013American\u2013British Cooperative Group. Ann Intern Med 1985; 103: 620\u2013625.","journal-title":"Ann Intern Med"},{"key":"BF2403873_CR10","doi-asserted-by":"publisher","first-page":"460","DOI":"10.7326\/0003-4819-103-3-460","volume":"103","author":"JM Bennett","year":"1985","unstructured":"Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French\u2013American\u2013British Cooperative Group. Ann Intern Med 1985; 103: 460\u2013462.","journal-title":"Ann Intern Med"},{"key":"BF2403873_CR11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/j.1365-2141.1991.tb04444.x","volume":"78","author":"JM Bennett","year":"1991","unstructured":"Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). Br J Haematol 1991; 78: 325\u2013329.","journal-title":"Br J Haematol"},{"key":"BF2403873_CR12","unstructured":"Creutzig U, Zimmermann M, Ritter J, Reinhardt D, Hermann J, Henze G, et al., for the AML-BFM Study Group. Treatment strategy and long-term results in pediatric patients treated in four consecutive AML-BFM trials. Leukemia, this issue."},{"key":"BF2403873_CR13","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1182\/blood.V62.2.315.315","volume":"62","author":"HJ Weinstein","year":"1983","unstructured":"Weinstein HJ, Mayer RJ, Rosenthal DS, Coral FS, Camitta BM, Gelber RD . Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update. Blood 1983; 62: 315\u2013319.","journal-title":"Blood"},{"key":"BF2403873_CR14","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1182\/blood.V61.2.297.297","volume":"61","author":"A Inati","year":"1983","unstructured":"Inati A, Sallan SE, Cassady JR, Hitchcock-Bryan S, Clavell LA, Belli JA et al. Efficacy and morbidity of central nervous system \u2018prophylaxis\u2019 in childhood acute lymphoblastic leukemia: eight years\u2019 experience with cranial irradiation and intrathecal methotrexate. Blood 1983; 61: 297\u2013303.","journal-title":"Blood"},{"key":"BF2403873_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1055\/s-2002-19861","volume":"214","author":"D Reinhardt","year":"2002","unstructured":"Reinhardt D, Thiele C, Creutzig U . Neuropsychological sequelae in children with AML treated with or without prophylactic CNS-irradiation. Klin P\u00e4diatr 2002; 214: 22\u201329.","journal-title":"Klin P\u00e4diatr"},{"key":"BF2403873_CR16","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1200\/JCO.2000.18.18.3273","volume":"18","author":"W Leung","year":"2000","unstructured":"Leung W, Hudson MM, Strickland DK, Phipps S, Srivastava DK, Ribeiro RC et al. Late effects of treatment in survivors of childhood acute myeloid leukemia. J Clin Oncol 2000; 18: 3273\u20133279.","journal-title":"J Clin Oncol"},{"key":"BF2403873_CR17","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/S0140-6736(84)91350-3","volume":"1","author":"R Champlin","year":"1984","unstructured":"Champlin R, Jacobs A, Gale RP, Boccia R, Elashoff R, Foon K et al. Prolonged survival in acute myelogenous leukaemia without maintenance chemotherapy. Lancet 1984; 1: 894\u2013896.","journal-title":"Lancet"},{"key":"BF2403873_CR18","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1200\/JCO.1994.12.11.2367","volume":"12","author":"RJ Wells","year":"1994","unstructured":"Wells RJ, Woods WG, Buckley JD, Odom LF, Benjamin D, Bernstein I et al. Treatment of newly diagnosed children and adolescents with acute myeloid leukemia: a Childrens Cancer Group study. J Clin Oncol 1994; 12: 2367\u20132377.","journal-title":"J Clin Oncol"},{"key":"BF2403873_CR19","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1200\/JCO.2002.07.300","volume":"20","author":"Y Perel","year":"2002","unstructured":"Perel Y, Auvrignon A, Leblanc T, Vannier JP, Michel G, Nelken B et al. Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89\/91. J Clin Oncol 2002; 20: 2774\u20132782.","journal-title":"J Clin Oncol"},{"key":"BF2403873_CR20","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1038\/sj.leu.2403131","volume":"17","author":"BL Abbott","year":"2003","unstructured":"Abbott BL, Rubnitz JE, Tong X, Srivastava DK, Pui CH, Ribeiro RC et al. Clinical significance of central nervous system involvement at diagnosis of pediatric acute myeloid leukemia: a single institution's experience. Leukemia 2003; 17: 2090\u20132096.","journal-title":"Leukemia"},{"key":"BF2403873_CR21","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/sj.leu.2402046","volume":"15","author":"U Creutzig","year":"2001","unstructured":"Creutzig U, Ritter J, Zimmermann M, Hermann J, Gadner H, Sawatzki DB et al. Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. Leukemia 2001; 15: 348\u2013354.","journal-title":"Leukemia"},{"key":"BF2403873_CR22","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1200\/JCO.2001.19.10.2705","volume":"19","author":"U Creutzig","year":"2001","unstructured":"Creutzig U, Ritter J, Zimmermann M, Reinhardt D, Hermann J, Berthold F et al. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin\u2013Frankfurt\u2013M\u00fcnster 93. J Clin Oncol 2001; 19: 2705\u20132713.","journal-title":"J Clin Oncol"},{"key":"BF2403873_CR23","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood.V77.8.1666.1666","volume":"77","author":"E Berman","year":"1991","unstructured":"Berman E, Heller G, Santorsa J, McKenzie S, Gee T, Kempin S et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991; 77: 1666\u20131674.","journal-title":"Blood"},{"key":"BF2403873_CR24","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1182\/blood.V79.2.313.313","volume":"79","author":"PH Wiernik","year":"1992","unstructured":"Wiernik PH, Banks PL, Case Jr DC, Arlin ZA, Periman PO, Todd MB et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992; 79: 313\u2013319.","journal-title":"Blood"},{"key":"BF2403873_CR25","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1200\/JCO.1992.10.7.1103","volume":"10","author":"WR Vogler","year":"1992","unstructured":"Vogler WR, Velez-Garcia E, Weiner RS, Flaum MA, Bartolucci AA, Omura GA et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. J Clin Oncol 1992; 10: 1103\u20131111.","journal-title":"J Clin Oncol"},{"key":"BF2403873_CR26","first-page":"34","volume":"20","author":"F Sackmann-Muriel","year":"1993","unstructured":"Sackmann-Muriel F, Fernandez-Barbieri MA, Santarelli MT, Matus-Ridley M, Rosso A, Negri-Aranguren P et al. Results of treatment with an intensive combination induction regimen containing idarubicin in children with acute myeloblastic leukemia: preliminary report of the Argentine Group for Treatment of Acute Leukemia. Semin Oncol 1993; 20: 34\u201338.","journal-title":"Semin Oncol"},{"key":"BF2403873_CR27","first-page":"6525","volume":"50","author":"JM Reid","year":"1990","unstructured":"Reid JM, Pendergrass TW, Krailo MD, Hammond GD, Ames MM . Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Children's Cancer Study Group report. Cancer Res 1990; 50: 6525\u20136528.","journal-title":"Cancer Res"},{"key":"BF2403873_CR28","first-page":"835","volume":"63","author":"AM Casazza","year":"1979","unstructured":"Casazza AM . Experimental evaluation of anthracycline analogs. Cancer Treat Rep 1979; 63: 835\u2013844.","journal-title":"Cancer Treat Rep"},{"key":"BF2403873_CR29","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1182\/blood.V69.3.744.744","volume":"69","author":"W Hiddemann","year":"1987","unstructured":"Hiddemann W, Kreutzmann H, Straif K, Ludwig WD, Mertelsmann R, Donhuijsen-Ant R et al. High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia. Blood 1987; 69: 744\u2013749.","journal-title":"Blood"},{"key":"BF2403873_CR30","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1200\/JCO.1993.11.6.1046","volume":"11","author":"S Amadori","year":"1993","unstructured":"Amadori S, Testi AM, Aric\u00f2 M, Comelli A, Giuliano M, Madon E et al. Prospective comparative study of bone marrow transplantation and post-remission chemotherapy for childhood acute myelogenous leukemia. J Clin Oncol 1993; 11: 1046\u20131054.","journal-title":"J Clin Oncol"},{"key":"BF2403873_CR31","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1182\/blood.V82.12.3730.3730","volume":"82","author":"K Tiedemann","year":"1993","unstructured":"Tiedemann K, Waters KD, Tauro GP, Tucker D, Ekert H . Results of intensive therapy in childhood acute myeloid leukemia, incorporating high-dose melphalan and autologous bone marrow transplantation in first complete remission. Blood 1993; 82: 3730\u20133738.","journal-title":"Blood"},{"key":"BF2403873_CR32","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/sj.leu.2403188","volume":"18","author":"T Lehrnbecher","year":"2004","unstructured":"Lehrnbecher T, Varwig D, Kaiser J, Reinhardt D, Klingebiel T, Creutzig U . Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93. Leukemia 2004; 18: 72\u201377.","journal-title":"Leukemia"},{"key":"BF2403873_CR33","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1056\/NEJM199605303342203","volume":"334","author":"Y Ravindranath","year":"1996","unstructured":"Ravindranath Y, Yeager AM, Chang MN, Steuber CP, Krischer J, Graham-Pole J, et al., for the Pediatric Oncology Group. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. N Engl J Med 1996; 334: 1428\u20131434.","journal-title":"N Engl J Med"},{"key":"BF2403873_CR34","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1046\/j.1365-2141.2002.03697.x","volume":"118","author":"U Creutzig","year":"2002","unstructured":"Creutzig U, Reinhardt D . Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation? \u2013 a European view. Br J Haematol 2002; 118: 365\u2013377.","journal-title":"Br J Haematol"},{"key":"BF2403873_CR35","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1046\/j.1365-2141.2002.03701.x","volume":"118","author":"AR Chen","year":"2002","unstructured":"Chen AR, Alonzo TA, Woods WG, Arceci RJ . Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation? \u2013 an American view. Br J Haematol 2002; 118: 378\u2013384.","journal-title":"Br J Haematol"},{"key":"BF2403873_CR36","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1046\/j.1365-2141.1998.00677.x","volume":"101","author":"RF Stevens","year":"1998","unstructured":"Stevens RF, Hann IM, Wheatley K, Gray RG, on behalf of the MRC Childhood Leukaemia Working Party. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. Br J Haematol 1998; 101: 130\u2013140.","journal-title":"Br J Haematol"},{"key":"BF2403873_CR37","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1182\/blood-2002-10-3064","volume":"101","author":"EL Sievers","year":"2002","unstructured":"Sievers EL, Lange BJ, Alonzo TA, Gerbing RB, Bernstein ID, Smith FO et al. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 acute myeloid leukemia patients. Blood 2002; 101: 3398\u20133406.","journal-title":"Blood"},{"key":"BF2403873_CR38","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1038\/sj.leu.2403405","volume":"18","author":"N Feller","year":"2004","unstructured":"Feller N, Van der Pol MA, Van Stijn A, Weijers GW, Westra AH, Evertse BW et al. MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia 2004; 18: 1380\u20131390.","journal-title":"Leukemia"},{"key":"BF2403873_CR39","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1182\/blood-2002-12-3627","volume":"102","author":"ChM Zwaan","year":"2003","unstructured":"Zwaan ChM, Meshinchi S, Radich JP, Veerman AJP, Huismans DR, Munske L et al. FLT3 internal tandem duplication in 234 children with acute myeloid leukemia (AML): prognostic significance and relation to cellular drug resistance. Blood 2003; 102: 2387\u20132394.","journal-title":"Blood"},{"key":"BF2403873_CR40","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1038\/sj.leu.2403480","volume":"18","author":"B George","year":"2004","unstructured":"George B, Mathews V, Poonkuzhali B, Shaji RV, Srivastava A, Chandy M . Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: a single center experience. Leukemia 2004; 18: 1587\u20131590.","journal-title":"Leukemia"},{"key":"BF2403873_CR41","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.1200\/JCO.2003.05.086","volume":"21","author":"Y Ravindranath","year":"2003","unstructured":"Ravindranath Y . Down syndrome and acute myeloid leukemia: the paradox of increased risk for leukemia and heightened sensitivity to chemotherapy. J Clin Oncol 2003; 21: 3385\u20133387.","journal-title":"J Clin Oncol"},{"key":"BF2403873_CR42","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.1182\/blood-2002-07-1947","volume":"101","author":"ChM Zwaan","year":"2003","unstructured":"Zwaan ChM, Reinhardt D, Corbacioglu S, Van Wering ER, B\u00f6kkerink JP, Tissing WJ et al. Gemtuzumab ozogamicin: first clinical experiences in children with relapsed\/refractory acute myeloid leukemia treated on compassionate use basis. Blood 2003; 101: 3868\u20133871.","journal-title":"Blood"},{"key":"BF2403873_CR43","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/sj.leu.2402810","volume":"17","author":"FR Appelbaum","year":"2003","unstructured":"Appelbaum FR . New targets for therapy in acute myeloid leukemia. Leukemia 2003; 17: 492\u2013495.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/2403873.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2403873","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2403873.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T01:09:57Z","timestamp":1648775397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/2403873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,18]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["BF2403873"],"URL":"https:\/\/doi.org\/10.1038\/sj.leu.2403873","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8,18]]},"assertion":[{"value":"7 February 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2005","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2005","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}